Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Biocine's gp120 HIV vaccine

Executive Summary

Stimulated neutralizing antibodies to HIV-1, which persisted for up to six months, in healthy, uninfected volunteers, according to results of an 18-month Phase I study presented by James Kahn, University of California -- San Francisco, on June 8 at the conference on AIDS. Over a one-year period, 30 volunteers received four injections of either the vaccine combined with adjuvants, an oil and water emulsion called MF-59 or a bacterial fragment called muramyl tripeptide (MTP-PE). Twelve volunteers received either placebo or injections without the HIV vaccine antigen. All volunteers receiving the vaccine produced antibodies against HIV, and neutralizing antibodies were produced against a closely related isolate of the virus, UCSF said. "The vaccine appeared to have better staying power than some other experimental vaccines, as the antibodies persisted in the body for as much as six months after the third injection," a company release states.

You may also be interested in...



Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials

Shire Hopes To Sow Future Deals With $50M Venture Fund

Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth

UsernamePublicRestriction

Register

LL1133951

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel